FY2025 · ended Dec 31, 2025 · Revenue $172.35M, +627.8% YoY · Filed Feb 26, 2026
Syndax Pharmaceuticals, Inc. (SNDX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $172.4 million and a net loss of $285.4 million. Free cash flow was -$323.2 million. As of Sep 30, 2026 it held $551.1 million in cash and investments and $350.5 million in total debt.
Revenue (TTM)
$289.68M
+160.3% vs year-ago TTM
Net income (TTM)
$-209.48M
+32.8% vs year-ago TTM
Operating cash flow (TTM)
$-177.36M
+42.9% vs year-ago TTM
Free cash flow
$-323.17M
-101.2% vs prior year
EPS (TTM)
$-2.37
+34.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
88.20M
+2.5% vs prior year
Net cash
$200.55M
as of Sep 30, 2026
Operating margin
-61.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SNDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1395937
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | — | $139.7M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M |
| Diluted EPS | -$3.29 | -$3.72 | -$2.98 | -$2.46 | $0.46 |
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M |
| Free cash flow | -$323.2M | — | -$160.6M | -$133.7M | $29.0M |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Stockholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M |
| Cash and investments | $394.1M | $692.4M | $600.5M | $481.3M | $439.9M |
| Total debt | $351.5M | $339.9M | $1.6M | $1.1M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 10, 2026 | Jun 10, 2026 |
All 657 Syndax Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.